HER2 Support Group Forums - View Single Post - excellent results of small (7 patients) Duke her2 dendritic cell vaccine

Joanne S · 09-12-2007, 10:54 PM

Summary
Expert Review of Vaccines
August 2007, Vol. 6, No. 4, Pages 617-633
(doi:10.1586/14760584.6.4.617)



Dendritic cell vaccination
Owen Proudfoot, Dodie Pouniotis, Kuo-Ching Sheng, Bruce E Loveland and Geoffrey A Pietersz<SUP>

</IMG></SUP>† Author for correspondence

There has been a surge of interest in the use of dendritic cell (DC) vaccination as cellular immunotherapy for numerous cancers. Despite some encouraging results, this therapeutic modality is far from being considered as a therapy for cancer. This review will first discuss preclinical DC vaccination in murine models of cancer, with an emphasis on comparative studies investigating different methods of antigen priming. We will then comment on the various murine DC subsets and how these relate to human DC preparations used for clinical studies. Finally, the methodology used to generate human DCs and some recent clinical trials in several cancers are reviewed.

09-12-2007, 10:54 PM	#5
Joanne S Senior Member Join Date: Aug 2007 Location: Detroit Metropolitan Area, Michigan Posts: 592	Future Drugs: Dendritic cell vaccination Summary Expert Review of Vaccines August 2007, Vol. 6, No. 4, Pages 617-633 (doi:10.1586/14760584.6.4.617) <!-- End title of page and review --><!-- Start full text content --> <!-- abstract content -->Dendritic cell vaccination Owen Proudfoot, Dodie Pouniotis, Kuo-Ching Sheng, Bruce E Loveland and Geoffrey A Pietersz<SUP></IMG></SUP>† Author for correspondence There has been a surge of interest in the use of dendritic cell (DC) vaccination as cellular immunotherapy for numerous cancers. Despite some encouraging results, this therapeutic modality is far from being considered as a therapy for cancer. This review will first discuss preclinical DC vaccination in murine models of cancer, with an emphasis on comparative studies investigating different methods of antigen priming. We will then comment on the various murine DC subsets and how these relate to human DC preparations used for clinical studies. Finally, the methodology used to generate human DCs and some recent clinical trials in several cancers are reviewed. <!-- /abstract content --><!-- fulltext content --><!-- /fulltext content --> __________________ Aug06...Dx Age 50, IDC Left Breast, 6+/16 lymph nodes, Stg 3, ER+/PR+/HER2+ Sep06-Jan07...Mediport. Chemo: AC x 4, T x 4 Dec06-Nov07...Herceptin Feb12,2007...Surg MRM Left & SM Right, reconstruct w/expanders Mar07-Jun07...Saline Exp Jun07...Start Tamoxifen Jun07-Aug07...Rad x 25 Jun07-Oct07...Persistent fevers-unknown origin Jun07-Nov07...PT for Severe PMPS & Capsular Contracture Nov07...Surg Capsulectomy, Gel Implants, PMPS pain gone instantly. Feb08...NED 1st CANCERVERSARY!!!!! Feb08...2 months post surgery Caps Cont again :( Mar08...Stop Tamoxifen. Start Arimidex. Apr08...Sudden high fever, Hosp ICU 10 days, staph infect, emerg surg, implants removed. Outpt IVantibiotics Daily x 6 weeks Feb11...NED 5th CANCERVERSARY!!!!! Feb12...NED 6th CANCERVERSARY!!!!! Aug12...Spotting. Surg=D&C Sep12...STAGE IV = RARE BC METS TO UTERUS ILC ER+/PR+/HER2-Negative) (Different BC than originally diagnosed = IDC ER+/PR+/HER2+). Sep12...Stop Arimidex. Start Afinitor & Aromasin. Jan13...MRI = no progression no reduction Apr13...Progression. Stop Afinitor & Aromasin. Apr13...Start Chemo: Taxol & Carboplatin. Nov13...Scans & Pelvic 95+% Reduction. Nueropathy>Stop chemo start Fareston. Jan14...PET scan = no progression stable. May14...Pelvic > Bleeding & cramps. TMs up. May14...PET scan = uterine progression :( May14...Stop Fareston. Start Chemo: Xeloda.